Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant Nivo+CT is unknown. Here we report the results and correlates of two arms of the phase 2 platform NEOSTAR trial testing neoadjuvant Nivo+CT and Ipi+Nivo+CT with major pathologic response (MPR) as the primary endpoint. MPR rates were 32.1% (7/22, 80% confidence interval (CI) 18.7–43.1%) in the Nivo+CT arm and 50% (11/22, 80% CI 34.6–61.1%) in the Ipi+Nivo+CT arm; the primary endpoint was met in both arms. In patients without known tumor EGFR/ALK alterations, MPR rates were 41.2% (7/17) and 62.5% (10/16) in the Nivo+CT and Ipi+Nivo+CT groups, respectively. No new safety signals were observed in either arm. Single-cell sequencing and multi-platform immune profiling (exploratory endpoints) underscored immune cell populations and phenotypes, including effector memory CD8⁺ T, B and myeloid cells and markers of tertiary lymphoid structures, that were preferentially increased in the Ipi+Nivo+CT cohort. Baseline fecal microbiota in patients with MPR were enriched with beneficial taxa, such as Akkermansia, and displayed reduced abundance of pro-inflammatory and pathogenic microbes. Neoadjuvant Ipi+Nivo+CT enhances pathologic responses and warrants further study in operable NSCLC. (ClinicalTrials.gov registration: NCT03158129.)

We discovered and validated three intratumoral subregions with distinct MR perfusion imaging parameters. In addition to clinical-pathologic and genomic factors, intratumoral spatial heterogeneity c... Purpose To characterize intratumoral spatial heterogeneity at perfusion magnetic resonance (MR) imaging and investigate intratumoral heterogeneity as a predictor of recurrence-free survival (RFS) i...

Data generated from sources such as wearable sensors, medical imaging, personal health records, pathology records, and public health organizations have resulted in a massive information increase in the medical sciences over the last decade. Advances in computational hardware, such as cloud computing, Graphical Processing Units (GPUs), and Tensor Processing Units (TPUs), provide the means to utilize these data. Consequently, many Artificial Intelligence (AI)-based methods have been developed to infer from large healthcare data. Here, we present an overview of recent progress in artificial intelligence and biosensors in medical and life sciences. We discuss the role of machine learning in medical imaging, precision medicine, and biosensors for the Internet of Things (IoT). We review the most recent advancements in wearable biosensing technologies that use AI to assist in monitoring bodily electro-physiological and electro-chemical signals and disease diagnosis, demonstrating the trend towards personalized medicine with highly effective, inexpensive, and precise point-of-care treatment. Furthermore, an overview of the advances in computing technologies, such as accelerated artificial intelligence, edge computing, and federated learning for medical data, are also documented. Finally, we investigate challenges in data-driven AI approaches, the potential issues that biosensors and IoT-based healthcare generate, and the distribution shifts that occur among different data modalities, concluding with an overview of future prospects.

The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between predictive and prognostic biomarkers can be challenging due to the overlap between the two. A prognostic biomarker predicts the future outcome of cancer, regardless of treatment, and a predictive biomarker predicts the effectiveness of a therapeutic intervention. Misclassifying a prognostic biomarker as predictive (or vice versa) can have serious financial and personal consequences for patients. To address this issue, various statistical and machine learning approaches have been developed. The aim of this study is to present an in-depth analysis of recent advancements, trends, challenges, and future prospects in biomarker identification. A systematic search was conducted using PubMed to identify relevant studies published between 2017 and 2023. The selected studies were analyzed to better understand the concept of biomarker identification, evaluate machine learning methods, assess the level of research activity, and highlight the application of these methods in cancer research and treatment. Furthermore, existing obstacles and concerns are discussed to identify prospective research areas. We believe that this review will serve as a valuable resource for researchers, providing insights into the methods and approaches used in biomarker discovery and identifying future research opportunities.

In this study, the authors identified prognostic imaging signatures in patients with early-stage non–small cell lung cancer by using a quantitative radiomic approach; if prospectively validated, th... Purpose To identify quantitative imaging biomarkers at fluorine 18 (18F) positron emission tomography (PET) for predicting distant metastasis in patients with early-stage non–small cell lung cancer...